The CRISPR companies are not OK

Gene editing promised a revolution, but layoffs, stock slumps, and industry struggles reveal a stark reality: Profits are elusive.

February 6, 2025 Check out STAT+

Sponsored By

Photo illustration: Christine Kao/STAT; Photos: Adobe STAT+ | The CRISPR companies are not OK Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably. By Jason Mast Opinion: FDA clinical trial inclusivity guidelines will be back As I've seen in my work with the FDA, clinical trial diversity guidelines are necessary to make sure medications are safe and effective for everyone. By Suzanne B. Robotti Opinion: Want to keep schools safe? Hire more nurses More than one-third of public schools don't have a full-time nurse. That puts student safety at risk. By Sherrie Page Guyer Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug STAT reporters discuss the downturn in the field of CRISPR gene editing and the advancement of RFK Jr.'s nomination. By Elaine Chen and Adam Feuerstein STAT+ | Previewing Immunovant's myasthenia gravis study readout — with all its quirky nuance In this edition of Adam's Biotech Scorecard, a look at upcoming results that will help determine whether batoclimab can compete against Argenx's Vyvgart.  By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser